TP53 and neoplasm: This indicates that, in the primary OXA-resistant HCT116/L tumor model, cGAMP can significantly and effectively inhibit the PI3K/AKT signaling pathway, thereby increasing p53 expression, and the effect is more obvious when combined with OXA (Figure 5C–E), which is consistent with the above anti-tumor research results.